Increasing treatment options for cannabis dependence: A review of potential pharmacotherapies

Anggadiredja, 2003, Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice, Brain Res., 966, 47, 10.1016/S0006-8993(02)04169-0 Anthony, 1995, Epidemiology of drug dependence, 361 Anthony, 1994, Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey, Exp. Clin. Psychopharmacol., 2, 244, 10.1037/1064-1297.2.3.244 Arseneault, 2004, Causal association between cannabis and psychosis: examination of the evidence, Br. J. Psychiatr., 84, 110, 10.1192/bjp.184.2.110 Ascher, 1995, Bupropion: a review of its mechanism of antidepressant activity, J. Clin. Psychiatr., 56, 395 Baumgartner, 1987, Clonidine vs. chlordiazepoxide in the management of acute alcohol withdrawal syndrome, Arch. Intern. Med., 147, 1223, 10.1001/archinte.147.7.1223 Beardsley, 2000, Effects of the cannabinoid CB receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal, Eur. J. Pharmacol., 387, 47, 10.1016/S0014-2999(99)00792-X Beardsley, 1986, Dependence on tetrahydrocannabinol in rhesus monkeys, J. Pharmacol. Exp. Ther., 239, 311 Benowitz, 1998, Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine, J. Pharmacol. Exp. Ther., 287, 958 Bhana, 2002, The South African Community Epidemiology Network on Drug Use (SACENDU) project, phases 1–8-cannabis and Mandrax, S. Afr. Med. J., 92, 542 Bolla, 2002, Dose-related neurocognitive effects of marijuana use, Neurology, 59, 1337, 10.1212/01.WNL.0000031422.66442.49 Braida, 2001, Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system, Neuroscience, 104, 923, 10.1016/S0306-4522(01)00210-X Braida, 2001, Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system, Eur. J. Pharmacol., 413, 227, 10.1016/S0014-2999(01)00766-X Budney, 1999, Marijuana withdrawal among adults seeking treatment for marijuana dependence, Addiction, 94, 1311, 10.1046/j.1360-0443.1999.94913114.x Budney, 2001, Marijuana abstinence effects in marijuana smokers maintained in their home environment, Arch. Gen. Psychiatr., 58, 917, 10.1001/archpsyc.58.10.917 Budney, 2003, The time course and significance of cannabis withdrawal, J. Abnorm. Psychol., 112, 393, 10.1037/0021-843X.112.3.393 Budney, 2004, Review of the validity and significance of cannabis withdrawal syndrome, Am. J. Psychiatr., 161, 1967, 10.1176/appi.ajp.161.11.1967 Caberlotto, 2004, Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?, Neuropsychopharmacology, 29, 15, 10.1038/sj.npp.1300296 Carter, 1997, Integrative functions of lactational hormones in social behavior and stress management, Ann. N.Y. Acad. Sci., 807, 164, 10.1111/j.1749-6632.1997.tb51918.x Chapman, 1982, Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C] glucose into amino acids, Neurochem. Res., 7, 1089, 10.1007/BF00964888 Chen, 2003, Possible age-associated bias in reporting of clinical features of drug dependence: epidemiological evidence on adolescent-onset marijuana use, Addiction, 98, 71, 10.1046/j.1360-0443.2003.00237.x Chen, 1990, Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis, Psychopharmacology, 102, 156, 10.1007/BF02245916 Coffey, 2002, Cannabis dependence in young adults: an Australian population study, Addiction, 97, 187, 10.1046/j.1360-0443.2002.00029.x Comer, 2001, Buprenorphine sublingual tablets: effects of IV heroin self-administration by humans, Psychopharmacology, 154, 28, 10.1007/s002130000623 Cone, 1988, Clonidine partially blocks the physiologic effects but not the subjective effects produced by smoking marijuana in male human subjects, Pharmacol. Biochem. Behav., 29, 649, 10.1016/0091-3057(88)90035-4 Copeland, 2001, Clinical profile of participants in a brief intervention program for cannabis use disorder, J. Subst. Abuse Treat., 20, 45, 10.1016/S0740-5472(00)00148-3 Cui, 2001, Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation, J. Neurosci., 21, 9867, 10.1523/JNEUROSCI.21-24-09867.2001 Cusack, 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds, Psychopharmacology, 114, 559, 10.1007/BF02244985 Dewey, 1972, Some pharmacological and toxicological effects of 1-trans-8 and 1-trans-9-tetrahydrocannabinol in laboratory rodents, Arch. Int. Pharmacodyn. Ther., 196, 133 Diana, 1998, Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids, Eur. J. Neurosci., 10, 2825, 10.1111/j.1460-9568.1998.00292.x Donovan, 2000, Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design, Am. J. Psychiatr., 157, 818, 10.1176/appi.ajp.157.5.818 Dworkin, 1995, Response-dependent versus response-independent presentation of cocaine: differences in the lethal effects of the drug, Psychopharmacology, 117, 262, 10.1007/BF02246100 Exner, 1995, Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex, Naunyn. Schmiedebergs. Arch. Pharmacol., 351, 46, 10.1007/BF00169063 Fattore, 2001, Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats, Psychopharmacology, 156, 410, 10.1007/s002130100734 Fawcett, 1995, Response of anxiety and agitation symptoms during nefazodone treatment of major depression, J. Clin. Psychiatr., 56, 37 Fielding, 1978, A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions, J. Pharmacol. Exp. Ther., 207, 899 Fischman, 1998, Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers, Behav. Pharmacol., 9, 479, 10.1097/00008877-199811000-00002 Fryer, 1999, Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function, J. Neurochem., 72, 1117, 10.1046/j.1471-4159.1999.0721117.x Gardner, 2002, Addictive potential of cannabinoids: the underlying neurobiology, Chem. Phys. Lipids, 121, 267, 10.1016/S0009-3084(02)00162-7 Gerasimov, 2000, Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study, J. Pharmacol. Exp. Ther., 295, 51 Giakas, 1990, Valproate in the treatment of temper outbursts, J. Clin. Psychiatr., 51, 525 Gold, 1978, Clonidine blocks acute opiate-withdrawal symptoms, Lancet, 2, 599, 10.1016/S0140-6736(78)92823-4 Greenwald, 2000, Antinociceptive, subjective and behavioral effects of smoked marijuana in humans, Drug Alcohol Depend., 59, 261, 10.1016/S0376-8716(99)00128-3 Haney, 1999, Abstinence symptoms following oral THC administration to humans, Psychopharmacology, 141, 385, 10.1007/s002130050848 Haney, 1999, Abstinence symptoms following smoked marijuana in humans, Psychopharmacology, 141, 395, 10.1007/s002130050849 Haney, 2001, Bupropion SR worsens mood during marijuana withdrawal in humans, Psychopharmacology, 155, 171, 10.1007/s002130000657 Haney, 2003, Nefazodone decreases anxiety during marijuana withdrawal in humans, Psychopharmacology, 165, 157, 10.1007/s00213-002-1210-3 Haney, 2003, Interaction between naltrexone and oral THC in heavy marijuana smokers, Psychopharmacology, 166, 77, 10.1007/s00213-002-1279-8 Haney, 2004, Marijuana withdrawal in humans: effects of oral THC or divalproex, Neuropsychopharmacology, 29, 158, 10.1038/sj.npp.1300310 Harris, 1974, Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys, Psychopharmacologia, 37, 23, 10.1007/BF00426679 Hart, 2001, Pharmacotherapies used in common substance use disorders, 303 Hart, 2002, Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans, Psychopharmacology, 164, 407, 10.1007/s00213-002-1231-y Hart, 2002, Effects of oral THC maintenance on smoked marijuana self-administration, Drug Alcohol Depend., 67, 301, 10.1016/S0376-8716(02)00084-4 Hart, C.L., Haney, M., Vosburg, S.K., Comer, S.D., Foltin, R.W., in press. Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology, 2005 Apr 14; [Epub ahead of print]. Hemby, 1997, Differences in extracellular dopamine concentrations in the nucleus accumbens during response-dependent and response-independent cocaine administration in the rat, Psychopharmacology, 133, 7, 10.1007/s002130050365 Henquet, 2005, Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people, Br. Med. J., 330, 11, 10.1136/bmj.38267.664086.63 Herkenham, 1995, Localization of cannabinoid receptors in the brain and periphery, 145 Hillier, 1980, Regulation of noradrenaline overflow in rat cerebral cortex by prostaglandin E2, Br. J. Pharmacol., 70, 469, 10.1111/j.1476-5381.1980.tb08725.x Huestis, 2001, Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716, Arch. Gen. Psychiatr., 58, 322, 10.1001/archpsyc.58.4.322 Huttenlocker, 1997, Developmental anatomy of prefrontal cortex, 69 Iversen, 2003, Cannabis and the brain, Brain, 126, 1252, 10.1093/brain/awg143 Jones, 1976, Clinical studies of cannabis tolerance and dependence, Ann. N.Y. Acad. Sci., 282, 221, 10.1111/j.1749-6632.1976.tb49901.x Jones, 1981, Clinical relevance of cannabis tolerance and dependence, J. Clin. Pharm., 21, 143S, 10.1002/j.1552-4604.1981.tb02589.x 1999 Justinova, 2003, Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys, Psychopharmacology, 169, 135, 10.1007/s00213-003-1484-0 Justinova, 2004, The opioid antagonist naltrexone reduces the reinforcing effects of Delta(9)-tetrahydrocannabinol (THC) in squirrel monkeys, Psychopharmacology, 173, 186, 10.1007/s00213-003-1693-6 Karler, 1980, Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice, Br. J. Pharmacol., 68, 479, 10.1111/j.1476-5381.1980.tb14562.x Kaymakcalan, 1973, Tolerance to and dependence on cannabis, Bull. Narc., 25, 39 Kaymakcalan, 1977, Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats, Psychopharmacology, 55, 243, 10.1007/BF00497855 Kouri, 1999, Changes in aggressive behavior during withdrawal from long-term marijuana use, Psychopharmacology, 43, 302, 10.1007/s002130050951 Kouri, 2000, Abstinence symptoms during withdrawal from chronic marijuana use, Exp. Clin. Psychopharmacol., 8, 483, 10.1037/1064-1297.8.4.483 Levin, 2004, Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium, Am. J. Addict., 13, 21, 10.1080/10550490490265280 Lichtman, 2001, Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine, Pharmacol. Biochem. Behav., 69, 181, 10.1016/S0091-3057(01)00514-7 McLean, 1986, Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture, J. Pharmacol. Exp. Ther., 237, 1001 McRae, 2003, Treatment of marijuana dependence: a review of the literature, J. Subst. Abuse Treat., 24, 369, 10.1016/S0740-5472(03)00041-2 Mansbach, 1994, Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys, Behav. Pharmacol., 5, 219, 10.1097/00008877-199404000-00014 Manzanares, 1999, Pharmacological and biochemical interactions between opioids and cannabinoids, Trends Pharmacol. Sci., 20, 287, 10.1016/S0165-6147(99)01339-5 Marijuana Treatment Project Research Group (MTPRG), 2004, Brief treatments for cannabis dependence: findings from a randomized multisite trial, J. Consult. Clin. Psychol., 72, 455, 10.1037/0022-006X.72.3.455 Mendelson, 1984, Marijuana withdrawal syndrome in a woman, Am. J. Psychiatr., 141, 1289, 10.1176/ajp.141.10.1289 Moore, 2003, Relapse in outpatient treatment for marijuana dependence, J. Subst. Abuse Treat., 25, 85, 10.1016/S0740-5472(03)00083-7 Navarro, 1998, CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats, Neuroreport, 9, 3397, 10.1097/00001756-199810260-00012 Navarro, 2001, Functional interaction between opioid and cannabinoid receptors in drug self-administration, J. Neurosci., 21, 5344, 10.1523/JNEUROSCI.21-14-05344.2001 Neumann, 2000, Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats, Neuroscience, 95, 567, 10.1016/S0306-4522(99)00433-9 Neumann, 2000, Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus, J. Neuroendocrinol., 12, 235, 10.1046/j.1365-2826.2000.00442.x Parale, 1986, Studies with alpha 2-adrenoceptor agonists and alcohol abstinence syndrome in rats, Psychopharmacology, 88, 237, 10.1007/BF00652247 Pertwee, 1997, Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol. Ther., 74, 129, 10.1016/S0163-7258(97)82001-3 Phillips, 1982, The effects of sodium valproate on gamma-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice, Biochem. Pharmacol., 31, 2257, 10.1016/0006-2952(82)90111-3 Pickens, 1973, Cannabis and phencyclidine self-administration by animals, 78 Pope, 2002, Cognitive measures in long-term cannabis users, J. Clin. Pharmacol., 42, 41S, 10.1002/j.1552-4604.2002.tb06002.x Pope, 2003, Early-onset cannabis use and cognitive deficits: what is the nature of the association?, Drug Alcohol Depend., 69, 303, 10.1016/S0376-8716(02)00334-4 Rodriguez de Fonseca, 1997, Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal, Science, 276, 2050, 10.1126/science.276.5321.2050 Sim, 1996, Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum, Eur. J. Pharmacol., 307, 97, 10.1016/0014-2999(96)00211-7 Slemmer, 2000, Bupropion is anicotinic antagonist, J. Pharmacol. Exp. Ther., 295, 321 Solowij, 2002, Cognitive functioning of long-term heavy cannabis users seeking treatment, JAMA, 287, 1123, 10.1001/jama.287.9.1123 Stephens, 1993, Adult marijuana users seeking treatment, J. Consult. Clin. Psychol., 61, 1100, 10.1037/0022-006X.61.6.1100 Stephens, 2002, The Marijuana Treatment Project: rationale, design and participant characteristics, Addiction, 97, 109, 10.1046/j.1360-0443.97.s01.6.x Substance Abuse and Mental Health Services Administration (SAMHSA), 2003. Overview of findings from the 2002 National Survey on Drug Use and Health (Office of Applied Studies, NHSDA Series H-21, DHHS Publication No. SMA 03-3774). Rockville, MD. Szabo, 2002, Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids, Eur. J. Neurosci., 15, 2057, 10.1046/j.1460-9568.2002.02041.x Tanda, 1997, Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism, Science, 276, 2048, 10.1126/science.276.5321.2048 Tanda, 1999, Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol, Eur. J. Pharmacol., 376, 23, 10.1016/S0014-2999(99)00384-2 Tanda, 2000, Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys, Nat. Neurosci., 3, 1073, 10.1038/80577 Tanda, 2003, Cannabinoids: reward, dependence, and underlying neurochemical mechanisms – a review of recent preclinical data, Psychopharmacology, 169, 115, 10.1007/s00213-003-1485-z Taylor, 1995, Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug, J. Clin. Psychiatr., 56, 3 Treatment Episode Data Set (TEDS) 1992–2002, 2002. National Admissions to Substance Abuse Treatment Services. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Rockville, MD, U.S. URL: http://www.oas.samhsa.gov/2k5/MJstateTrends/MJstateTrends.htm. Uhde, 1980, Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study, Psychiatr. Res., 2, 37, 10.1016/0165-1781(80)90005-0 UNODCCP, 2002 Uvnas-Moberg, 1994, High doses of oxytocin cause sedation and low doses cause an anxiolytic-like effect in male rats, Pharmacol. Biochem. Behav., 49, 101, 10.1016/0091-3057(94)90462-6 Van Hoozen, 1997, Marijuana. Respiratory tract effects, Clin. Rev. Allergy Immunol., 15, 243, 10.1007/BF02737700 Verberne, 1981, Attenuation of delta 9-tetrahydrocannabinol-induced withdrawal-like behaviour by delta 9-tetrahydrocannabinol, Psychopharmacology, 73, 97, 10.1007/BF00431112 Verberne, 1980, Withdrawal-like behaviour induced by inhibitors of biogenic amine reuptake in rats treated chronically with delta 9-tetrahydrocannabinol, Psychopharmacology, 68, 261, 10.1007/BF00428113 Wachtel, 2002, Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans, Psychopharmacology, 161, 331, 10.1007/s00213-002-1033-2 Woods, 1987, Abuse liability of benzodiazepines, Pharmacol. Rev., 39, 251 Woods, 1992, Benzodiazepines: use, abuse, and consequences, Pharmacol. Rev., 44, 151 Zajecka, 1996, The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings, J. Clin. Psychiatr., 57, 10 Zimmer, 1997